

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-018-4772-2>

| Islet preparation | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 ^a |
|---|----------|----------------------------|----------------------------|----------|--------------------------|-------------------|----------|----------------|
| MANDATORY INFORMATION | | | | | | | | |
| Unique identifier | HPAP-020 | HPAP-021 | HPAP-023 | HPAP-026 | HPAP-028 | HPAP-032 | HPAP-034 | HPAP-036 |
| Donor age (years) | 14 | 13 | 17 | 24 | 4 | 10 | 13 | 23 |
| Donor sex (M/F) | M | F | F | M | M | F | M | F |
| Donor BMI (kg/m ²) | 13.2 | 21.4 | 21.35 | 20.8 | 17.3 | 16.3 | 18.6 | 16 |
| Donor HbA _{1c} or other measure of blood glucose control | NA | NA | 8.9 | 4.9 | 9.8 | 9 | 5.2 | 5.2 |
| Origin/source of islets ^b | nPOD | nPOD | nPOD | nPOD | nPOD | nPOD | UPENN | nPOD |
| Islet isolation centre | nPOD | nPOD | nPOD | nPOD | nPOD | nPOD | UPENN | nPOD |
| Donor history of diabetes? Please select yes/no from drop down list | Yes | Yes | Yes | No | Yes | Yes | No | No |
| If Yes, complete the next two lines if this information is available | | | | | | | | |
| Diabetes duration (years) | 5 days | 7 | 7 | | 3 | 3 | | |
| Glucose-lowering therapy at time of death ^c | Insulin | Insulin (Tresiba, Novolog) | Insulin (Humalog, Levemir) | | Insulin (Lantis, Apidra) | Insulin (Humalog) | | |

Continues on the next page

| RECOMMENDED INFORMATION | | | | | | | | |
|---|-----|-----|-----|-----|-----|-----|-----|-----|
| Donor cause of death | DBD | DBD | DCD | DCD | DBD | DBD | DBD | DBD |
| Warm ischaemia time (h) | | | | | | | | |
| Cold ischaemia time (h) | | | | | | | | |
| Estimated purity (%) | 35 | 30 | 60 | 90 | 40 | 30 | 70 | 90 |
| Estimated viability (%) | 92 | 93 | 95 | 92 | 88 | 88 | 95 | 92 |
| Total culture time (h) ^d | | | | | | | | |
| Glucose-stimulated insulin secretion or other functional measurement ^e | | | | | | | | |
| Handpicked to purity? Please select yes/no from drop down list | | | | | | | | |
| Additional notes | | | | | | | | |

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-018-4772-2>

| Islet preparation | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
|---|----------|----------|----------|---------------------------------|----------|----------|----------|----------|
| MANDATORY INFORMATION | | | | | | | | |
| Unique identifier | HPAP-042 | HPAP-047 | HPAP-052 | HPAP-064 | HPAP-071 | HPAP-080 | HPAP-082 | HPAP-084 |
| Donor age (years) | 1 | 8 | 27 | 24 | 12 | 22 | 25 | 12 |
| Donor sex (M/F) | M | M | M | M | F | M | M | F |
| Donor BMI (kg/m ²) | 17.9 | 16.82 | 38.72 | 16.98 | 15.42 | 35.71 | 23.96 | 18.5 |
| Donor HbA _{1c} or other measure of blood glucose control | 5.6 | NA | 5.2 | 13 | 9.8 | 5.4 | 5.6 | 13.3 |
| Origin/source of islets ^b | nPOD | UPENN | UPENN | nPOD | nPOD | nPOD | nPOD | nPOD |
| Islet isolation centre | nPOD | UPENN | UPENN | nPOD | nPOD | nPOD | nPOD | nPOD |
| Donor history of diabetes? Please select yes/no from drop down list | No | No | No | Yes | Yes | No | No | Yes |
| If Yes, complete the next two lines if this information is available | | | | | | | | |
| Diabetes duration (years) | | | | Unknown, diagnosed at admission | 3 | | | Unknown |
| Glucose-lowering therapy at time of death ^c | | | | Insulin glargine | | | | Insulin |

Continues on the next page

| RECOMMENDED INFORMATION | | | | | | | | |
|---|-----|-----|-----|-----|-----|-----|-----|-----|
| Donor cause of death | DCD | DBD | DBD | DBD | DBD | DBD | DCD | DBD |
| Warm ischaemia time (h) | | | | | | | | |
| Cold ischaemia time (h) | | | | | | | | |
| Estimated purity (%) | 35 | 50 | 90 | 80 | 70 | 85 | 35 | 80 |
| Estimated viability (%) | 95 | 93 | 89 | 97 | 93 | 87 | 92 | 95 |
| Total culture time (h) ^d | | | | | | | | |
| Glucose-stimulated insulin secretion or other functional measurement ^e | | | | | | | | |
| Handpicked to purity? Please select yes/no from drop down list | | | | | | | | |
| Additional notes | | | | | | | | |

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-018-4772-2>

| Islet preparation | 17 | 18 | 19 | 20 | | | | |
|---|----------|----------|----------|---|--|--|--|--|
| MANDATORY INFORMATION | | | | | | | | |
| Unique identifier | HPAP-099 | HPAP-104 | HPAP-113 | HPAP-123 | | | | |
| Donor age (years) | 28 | 4 | 9 | 25 | | | | |
| Donor sex (M/F) | F | M | M | M | | | | |
| Donor BMI (kg/m ²) | 24.7 | 20.63 | 15.92 | 21.35 | | | | |
| Donor HbA _{1c} or other measure of blood glucose control | 5 | 4.9 | 11.1 | 9.7 | | | | |
| Origin/source of islets ^b | UPENN | UPENN | nPOD | nPOD | | | | |
| Islet isolation centre | UPENN | UPENN | nPOD | nPOD | | | | |
| Donor history of diabetes? Please select yes/no from drop down list | No | No | Yes | Yes | | | | |
| If Yes, complete the next two lines if this information is available | | | | | | | | |
| Diabetes duration (years) | | | Unknown | 3 | | | | |
| Glucose-lowering therapy at time of death ^c | | | Insulin | insulin glargine 100u/ml (13 units SQ) insulin regular, | | | | |

Continues on the next page

| RECOMMENDED INFORMATION | | | | | | | | |
|---|-----|-----|-----|-----|--|--|--|--|
| Donor cause of death | DBD | DBD | DBD | DBD | | | | |
| Warm ischaemia time (h) | | | | | | | | |
| Cold ischaemia time (h) | | | | | | | | |
| Estimated purity (%) | 85 | 90 | 80 | 90 | | | | |
| Estimated viability (%) | 95 | 96 | 94 | 90 | | | | |
| Total culture time (h) ^d | | | | | | | | |
| Glucose-stimulated insulin secretion or other functional measurement ^e | | | | | | | | |
| Handpicked to purity? Please select yes/no from drop down list | | | | | | | | |
| Additional notes | | | | | | | | |

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results